How should treatment‑emergent resistance to baloxavir marboxil be managed, including alternative antiviral choices and dosing adjustments?

Management of treatment‑emergent resistance to baloxavir marboxil

Switch immediately from baloxavir to a neuraminidase inhibitor (oseltamivir preferred; inhaled zanamivir or IV peramivir as alternatives), because cross‑resistance is not expected and NAIs retain activity against baloxavir‑resistant strains, which best protects morbidity, mortality, and quality of life. 1, 2, 3

Rationale and evidence priority

• Guideline first:
  • AAP/IDSA/CDC guidance cautions on baloxavir use (avoid in severely immunocompromised; cation interactions) and emphasizes alternative antivirals with renal/airway caveats; choose agents per patient factors and resistance surveillance 1. AAP 2024–2025 details pediatric resistance risk, especially H3N2 and age <5; advises using circulating strain data and indicates alternatives will be recommended if resistance emerges 2.
• FDA label (highest quality for drug-specific resistance/cross-resistance):
  • Cross‑resistance is not expected: oseltamivir is active against viruses with PA substitutions conferring reduced baloxavir susceptibility (e.g., I38T, E23K/G, E199G) 3. Avoid polyvalent cations with baloxavir; single‑dose dosing for treatment/PEP detailed 3.
• Research (supportive, not directive):
  • High pediatric emergence of PA‑I38X with baloxavir; associated with prolonged shedding and delayed recovery (worse QOL) 4. Combination data are limited; small case series in immunocompromised patients show unclear efficacy and resistance can still develop 5.

Stepwise algorithm (actionable)

1. Suspect or confirm baloxavir resistance

• Triggers:
  • Clinical nonresponse or rebound after baloxavir (especially H3N2 or age <5; immunocompromised). 2, 4
  • Prolonged viral shedding or deterioration.
• Do not wait for genotyping to change therapy if clinically failing.

1. Stop baloxavir; start a neuraminidase inhibitor (choose one)

• First‑line: Oseltamivir PO (preferred for most; best accessibility and safety) 1, 2.
  • Adults/adolescents ≥13 y: 75 mg PO twice daily x 5 days (extend to 10 days or until clinical/virologic improvement in severe disease or immunocompromise; real‑world practice).
  • Pediatrics per weight/age; adjust for renal impairment and for preterm infants by PMA as per AAP (consult Peds ID for extreme prematurity) 1.
• If inhaled route acceptable and no chronic airway disease: Zanamivir INH (avoid in asthma/COPD; never nebulize) 1.
• If oral absorption unreliable or severe disease needing parenteral therapy: Peramivir IV with renal dose adjustments (6 mo–12 y: 2–4 mg/kg per CrCl; ≥13 y: 100–200 mg per CrCl strata) 1.

1. Special populations and cautions

• Severely immunocompromised: Do not use baloxavir monotherapy; use NAI (often extended duration). Combination baloxavir+oseltamivir has insufficient outcome evidence and did not consistently prevent resistance; prioritize NAI and extend/monitor rather than rely on combination 1, 5.
• Pregnancy/lactation: Prefer oseltamivir; avoid baloxavir 1.
• Airway disease (asthma/COPD): Avoid inhaled zanamivir due to bronchospasm risk 1.
• Renal impairment: Adjust peramivir; adjust oseltamivir in moderate–severe CKD; monitor in preterm infants per PMA dosing 1.

1. Diagnostics and monitoring

• Obtain respiratory specimen for RT‑PCR and, if available, resistance testing; however, do not delay the NAI switch.
• Monitor clinical trajectory (fever, oxygenation), complications (bacterial superinfection), and consider isolation to limit spread of resistant virus 3.
• In immunocompromised or severe disease, consider serial PCR to guide duration.

1. Post‑exposure prophylaxis (PEP) for contacts when resistance suspected

• Prefer oseltamivir for PEP within 48 hours of exposure; avoid routine widespread PEP outside institutional outbreaks; tailor to high‑risk contacts per AAP 1.
• Avoid baloxavir PEP when the index case failed baloxavir or resistance suspected.

Dosing quick guide (key adjustments)

• Oseltamivir: Standard adult 75 mg BID x 5 days; pediatric weight‑based; reduce dose in CKD; lower doses for preterm infants by PMA 1.
• Zanamivir: Inhaled per label; avoid in reactive airway disease; not for nebulizers/ventilators 1.
• Peramivir: Single IV dose with renal adjustment as per AAP/FDA (peds and adults) 1.

Pitfalls to avoid

• Continuing baloxavir despite clinical failure; resistance (e.g., PA I38T) is more frequent in young children and H3N2 and prolongs infectious shedding (worse QOL and transmission) 2, 4.
• Assuming cross‑resistance: NAIs remain active against baloxavir‑resistant strains; use them promptly 3.
• Using zanamivir in asthma/COPD or via nebulizer—risk of bronchospasm and device misuse 1.
• Missing cation interactions that reduce baloxavir exposure (calcium, iron, magnesium, zinc, antacids); while stopping baloxavir in resistance, remember for future prescribing 1, 3.

When evidence diverges

• Limited/heterogeneous data on combination therapy (baloxavir+oseltamivir) show tolerability but no proven mortality/morbidity benefit and resistance may still emerge; therefore, choose a neuraminidase inhibitor as definitive therapy to protect outcomes 5. Animal/in vitro synergy exists but is not practice‑changing for patient‑level outcomes 6, 7.

One‑line contingency for severe/complicated cases

• If rapidly progressive or lower respiratory tract disease, start IV/PO NAI immediately (peramivir IV or oseltamivir PO), extend duration, and involve ID for resistance testing and course length; avoid baloxavir monotherapy in immunocompromised hosts 1, 2.